In Africa, the maternal mortality rate in sickle cell disease (SCD) is~10%. Our team previously demonstrated an 89% decrease in mortality rate in a before-and-after feasibility study among women with SCD living in low-resource setting in Ghana. In the same cohort including additional participants with and without SCD, we used a prospective cohort design to test the hypothesis that implementing a multidisciplinary care team for pregnant women with SCD in low-resource setting will result in similar maternal and perinatal mortality rates compared to women without SCD. We prospectively enrolled pregnant women with and without SCD or trait and followed them up for 6-week postpartum. We tested the newborns of mothers with SCD for SCD. We recruited age and parity matched pregnant women without SCD or trait as the comparison group. Maternal and perinatal mortality rates were the primary outcomes.
In Africa, the maternal mortality rate in sickle cell disease (SCD) is~10%. Our team previously demonstrated an 89% decrease in mortality rate in a before-and-after feasibility study among women with SCD living in low-resource setting in Ghana. In the same cohort including additional participants with and without SCD, we used a prospective cohort design to test the hypothesis that implementing a multidisciplinary care team for pregnant women with SCD in low-resource setting will result in similar maternal and perinatal mortality rates compared to women without SCD. We prospectively enrolled pregnant women with and without SCD or trait and followed them up for 6-week postpartum. We tested the newborns of mothers with SCD for SCD. We recruited age and parity matched pregnant women without SCD or trait as the comparison group. Maternal and perinatal mortality rates were the primary outcomes.
A total of 149 pregnant women with SCD (HbSS, 54; HbSC, 95) and 117 pregnant women without SCD or trait were included in the analysis. Post-intervention, maternal mortality rates were 1.3% and 0.9% in women with and without SCD, respectively (P = 1.00); the perinatal mortality rates were 7.4% and 3.4% for women with and without SCD, respectively (P = 0.164). Among the mothers with SCD,~15% of newborns had SCD. Multidisciplinary care of pregnant women with SCD may reduce maternal and perinatal mortality rates to similar levels in pregnant women without SCD in low-resource settings. Newborns of mothers with SCD have a high rate of SCD.
| INTRODUCTION
In sub-Saharan Africa, the risk of maternal death among pregnant women with sickle cell disease (SCD) is significantly higher compared to their non-SCD counterparts. 1 In a systematic review and metaanalysis our team demonstrated that SCD is associated with an increased risk of maternal death compared to women without SCD in low-resource settings (odds ratio [OR] 22.8 [95% CI 14.7-35.5], P < .001). 2 Acute chest syndrome (ACS) is a major cause of death among pregnant women with SCD. 3, 4 Other adverse maternal outcomes in women with SCD include hypertensive disorders of pregnancy (preeclampsia, eclampsia), severe anemia, urinary tract infections, and increased odds of both antenatal and postnatal acute pain episodes. 1, 2, [5] [6] [7] [8] [9] We have previously demonstrated, in a before-andafter study design, that multidisciplinary care of pregnant women with SCD reduced maternal mortality by 89% in a low-resource setting in sub-Saharan Africa. 10 In a prospective cohort study of pregnant women with and without SCD or sickle cell trait, we tested the hypothesis that multidisciplinary care of pregnant women with SCD in a low-resource setting will reduce maternal and perinatal mortality rates to similar levels in pregnant women without SCD.
2 | METHODOLOGY
| Study design and setting
The prospective cohort study included pregnant women with and without SCD at the Korle-Bu Teaching Hospital (KBTH), Accra, Ghana, Board, Nashville, TN, USA (VUMC IRB #141050). The KBTH is a tertiary referral hospital in the capital, Accra, and the largest specialist hospital in Ghana. The maternity unit attends to about 11 000 pregnant women annually including~200 pregnant women with SCD.
| Study population
The cases included pregnant women with SCD (HbSS or HbSC) as determined by cellulose acetate hemoglobin electrophoresis at alkaline pH. A comparison group included pregnant women without SCD or sickle cell trait attending the same antenatal clinic, matched for age and parity. Gestational age was estimated based on first trimester ultrasound scan. We excluded women who were referred with acute pregnancy-related complications, in active labor or after delivery, and those who were unable to comply with the follow-up requirements for prenatal visits.
| Implementation strategies
We constructed our intervention based on the organizational model of innovation 11 which posits that the implementation strategy, via changes in the implementation climate 12 and implementation fit, 13 influences implementation and clinical outcomes.
Our implementation strategy for this prospective study included a combination of 4 elements: Routine use of incentive spirometers, an evidence-based strategy demonstrated to prevent ACS in SCD, 15 was considered essential for patient management but was not financially sustainable in a lowresource setting. Instead, we improvised using latex balloons.
Repeated inflations were used as recommended routinely on the obstetric wards among pregnant women with SCD in place of incentive spirometers to prevent ACS during acute pain episodes and after cesarean sections. 15 Blown balloons were inspected at the bedside as documentation of completing the task. Measurement of oxygen saturation was integrated into routine clinical care. A protocol was established for the transfer of patients with ACS to the intensive care unit (ICU) for ventilatory support when necessary.
| Assessment of SCD status of newborns
Newborn screening was performed for babies of pregnant women with SCD to determine their hemoglobin genotype. The heel prick method was used to obtain samples on filter paper between day 2 and 6 weeks of birth. Isoelectric focusing method was used for the newborn screening of SCD. All Infants with a suspected diagnosis of SCD were referred to the pediatric SCD unit to continue medical care after 6 weeks postpartum.
Acute vaso-occlusive and ACS episodes
Acute vaso-occlusive pain was distinguished from labor pain based on the absence of uterine contractions, evidence of labor progression and delivery. ACS was defined based on the presence of at least 2 of the following criteria, including positive chest signs: temperature greater than 38 C, increased respiratory rate of >20 breaths per minute, positive chest pain or pulmonary auscultatory findings, increased oxygen requirement (SpO 2 drop >3% from a documented steady-state value on room air), and AE a new radio-density on chest roentgenogram. 16 In the absence of abdominal shielding, a chest X-ray was done for only postpartum women. A diagnosis of pneumonia was considered an ACS episode. All cases of acute vaso-occlusive pain and ACS episodes were adjudicated with the obstetricians and hematologists on the research team to ensure a uniform definition.
Evaluation for malaria
Malaria infection was defined using the World Health Organization gold standard of examining stained thick smears under the light microscope 17 and parasite density (graded as + through to ++++) 18 together with the presence of clinical symptoms of fever, general malaise/illness and worsening anemia. All pregnant women (with and without SCD) were evaluated for malaria infection using the same criteria, and all pregnant women who did not have Glucose-6-phosphate dehydrogenase (G6PD) deficiency were given anti-malarial prophylaxis using sulfadoxin-pyrimethamine combination therapy starting when fetal movements are first felt (quickening) and repeated at 4-weekly intervals until 36 weeks gestational ages. The rate of asymptomatic malaria parasitemia was also assessed.
Spirometry evaluation
Spirometry evaluation was performed for all study participants on study visits at enrolment, 28, 36, and 6 weeks postpartum using the Morgan Based on prior evidence, only the relationship between FEV 1 % predicted and acute pain and ACS incidence rate were included. 20 
| Statistical analysis
Simple descriptive statistics were used to summarize discrete and con- (1/117), respectively (P = 1.00). Perinatal mortality rate was comparable in women with and without SCD at 7.4% (11/149) and 3.4%
(4/117), respectively (P = .164). The small sample size of maternal (n = 3) and perinatal (n = 15) deaths, in both the women with and without SCD, precluded any multivariable analysis.
3.2 | Rates of preeclampsia and hospitalization for malaria was higher in pregnant women with SCD compared to those without SCD
The rate of preeclampsia in women with SCD was twice as high compared to pregnant women without SCD, 12.3% and 6.0% respectively (P = .081). The rate of hospitalization for malaria was significantly higher in pregnant women with SCD when compared to women without SCD at 23.5% and 11.8%, respectively (P = .022). The rates of cesarean delivery were similar in both cohorts (SCD: 57.6% and non-SCD: 49.6%; P = .193). There were no cases of asymptomatic malaria parasitemia.
3.3 | Preterm births and low birthweight infants were higher among pregnant women with SCD compared to women without SCD Preterm birth (<37 weeks) and LBW (<2500 g) were more frequent in pregnant women with SCD compared to women without SCD. The rates of preterm birth were 26.4% and 16.2%, respectively in women with and without SCD, (P = .048). There was a significantly higher rate of LBW infants among women with SCD compared to those without SCD, 25.2% and 12.9%, respectively (P = .014). Though the rate of very LBW (<1500 g) doubled in women with SCD compared to those without SCD, 5.6% and 2.6%, respectively, the difference was not significant (P = .233). Early preterm birth rates (<34 weeks) among women with SCD was almost twice that of women without SCD, though the difference was not significant, 11.5% and 6.0%, respectively (P = .121). The rate of intrauterine growth restriction (IUGR) in pregnant women with SCD was more than double that in women without SCD, 6.3% and 2.7%, respectively, but the difference was also not statistically significant (P = .175), Among all pregnant women in the cohort, preeclampsia was a risk factor for LBW (<2500 g; OR 6.4 [95% CI 2.5-16.9], P < .001; of participants with HbSS delivered preterm compared to 18% in those with HbSC (P = .003). In pregnant women with HbSS, the rate of early preterm birth was increased more than 3 times than in women with HbSC, 20.4% versus 6.4%, respectively (P = .010). The rate of LBW was significantly higher in pregnant women with HbSS compared to pregnant women with HbSC disease, 42.2% and 16.1%, respectively (P = .001). Approximately 13% of pregnant women with HbSS and 2.2% of pregnant women with HbSC had babies with IUGR (P = .013; Table 3 ).
3.6 | Preeclampsia, low BMI, and HbSS phenotypes were associated with premature delivery (<37 weeks) in women with SCD (Table 4) Table 4 ).
In another model to identify predictors of preeclampsia in pregnant women with SCD, none of the covariates, including maternal age, parity, hemoglobin phenotype, FEV 1 % predicted, or BMI predicted preeclampsia (Table 4) . 
| DISCUSSION
In a low-resource setting, pregnant women with SCD have a 22 higher odds ratio of death when compared to women without SCD in the same setting. 2 We previously demonstrated in a before-and-after study that a multidisciplinary care model reduced maternal mortality in women with SCD by nearly 90%. 10 In this prospective cohort study, we have confirmed that implementing a multidisciplinary care strategy reduced maternal and perinatal mortality in women with SCD to similar levels in those without SCD in a low-resource setting.
The implementation climate for this project at KBTH was developed from 2011 to 2015, when the obstetric leader (SAO) created an intra-disciplinary team for high-risk antenatal clinic for pregnant women with SCD at KBTH in Accra, Ghana. Previously, the clinic was staffed exclusively with obstetricians and midwives to care for pregnant women with SCD. Despite a dedicated clinic and team, the maternal mortality rate remained~10% 10 or 100 per 1000 live births.
Comparatively, in the United States, the maternal mortality rate was A unique attribute of our study of pregnant women with SCD is the high proportion of women with HbSS and HbSC allowing for a direct comparison of maternal and perinatal risk factors and outcomes between the 2 SCD phenotypes. Previous studies have reported higher rates of preterm birth and LBW among pregnant women with SCD compared to the non-SCD group. 8, [22] [23] [24] [25] In this study, preterm birth and LBW were increased in pregnant women with HbSS when compared to women with HbSC disease. In a Jamaican cohort study of 113 pregnant women with HbSC disease, preeclampsia was also associated with low birth weight. 26 Regardless of whether the participant had or did not have SCD, preeclampsia increased the risk of preterm birth and low birthweight in all pregnant women. Thus, targeting a strategy to prevent and treat preeclampsia among women with SCD in both lowand high-income countries would likely improve perinatal outcomes.
Furthermore, among women with SCD, each subsequent pregnancy was associated with a lower odds of low birthweight newborns.
Our study has anticipated strengths and weaknesses. The main strength of the study is that we have demonstrated after implementing low-technology strategies that in a low-resource environment, the high maternal and perinatal mortality rates in SCD can be decreased to comparable levels in women without SCD. Another distinctive strength of the study is that we have provided one of the few estimates for the prevalence of SCD (specifically HbSS and HbSC) in newborns of pregnant women with SCD living in West Africa. The observation that at least 15% of the newborns of mothers were diagnosed with SCD, compared to the 2% projected 27 in this region, highlights need for nationwide newborn screening for SCD; and targeting pre-conceptual genetic counseling in young adults with SCD may have a significant impact in making informed decisions about having a child with SCD.
Some identified weaknesses of the study include, our study being conducted at a tertiary care center; and may not be representative of community hospitals without a hematologist. Our multidisciplinary, low technology approach for decreasing maternal mortality, is an unproven strategy in non-tertiary facilities in low-resource settings.
We have initiated a strategy for implementing a multidisciplinary care strategy for decreasing maternal and perinatal deaths in pregnant women with SCD at other non-academic hospitals in Accra, Ghana.
In conclusion, implementation of a multidisciplinary care strategy at a tertiary care medical center for pregnant women with SCD reduced maternal and perinatal mortality to comparable levels in pregnant women without SCD in a low-resource setting. Further efforts to reduce perinatal morbidity must target preeclampsia and its impact on IUGR and prematurity.
